Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

MYM Nutraceuticals

DB:0MY
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0MY
DB
CA$13M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

MYM Nutraceuticals Inc. engages in the cultivation, extraction, and distribution of cannabis products. The last earnings update was 88 days ago. More info.


Add to Portfolio Compare Print
  • MYM Nutraceuticals has significant price volatility in the past 3 months.
0MY Share Price and Events
7 Day Returns
13.3%
DB:0MY
4.7%
DE Pharmaceuticals
2.1%
DE Market
1 Year Returns
-88.5%
DB:0MY
-7.9%
DE Pharmaceuticals
-16.6%
DE Market
0MY Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MYM Nutraceuticals (0MY) 13.3% -23.7% -22.1% -88.5% -76.6% 33.6%
DE Pharmaceuticals 4.7% -12.9% -18.4% -7.9% 10.1% -5.5%
DE Market 2.1% -12.6% -22.9% -16.6% -21.9% -27.8%
1 Year Return vs Industry and Market
  • 0MY underperformed the Pharmaceuticals industry which returned -7.9% over the past year.
  • 0MY underperformed the Market in Germany which returned -16.6% over the past year.
Price Volatility
0MY
Industry
5yr Volatility vs Market

0MY Value

 Is MYM Nutraceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for MYM Nutraceuticals. This is due to cash flow or dividend data being unavailable. The share price is €0.0374.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MYM Nutraceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MYM Nutraceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0MY PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-11-30) in CAD CA$-0.17
CNSX:MYM Share Price ** CNSX (2020-04-07) in CAD CA$0.08
Europe Pharmaceuticals Industry PE Ratio Median Figure of 56 Publicly-Listed Pharmaceuticals Companies 20.81x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 16.83x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MYM Nutraceuticals.

DB:0MY PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:MYM Share Price ÷ EPS (both in CAD)

= 0.08 ÷ -0.17

-0.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MYM Nutraceuticals is loss making, we can't compare its value to the Europe Pharmaceuticals industry average.
  • MYM Nutraceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does MYM Nutraceuticals's expected growth come at a high price?
Raw Data
DB:0MY PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.44x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 36 Publicly-Listed Pharmaceuticals Companies 1.74x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.22x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MYM Nutraceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MYM Nutraceuticals's assets?
Raw Data
DB:0MY PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-11-30) in CAD CA$0.05
CNSX:MYM Share Price * CNSX (2020-04-07) in CAD CA$0.08
Germany Pharmaceuticals Industry PB Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 1.71x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.45x
DB:0MY PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:MYM Share Price ÷ Book Value per Share (both in CAD)

= 0.08 ÷ 0.05

1.48x

* Primary Listing of MYM Nutraceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MYM Nutraceuticals is good value based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess MYM Nutraceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. MYM Nutraceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

0MY Future Performance

 How is MYM Nutraceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MYM Nutraceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.1%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MYM Nutraceuticals expected to grow at an attractive rate?
  • Unable to compare MYM Nutraceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare MYM Nutraceuticals's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare MYM Nutraceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:0MY Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 13.1%
Europe Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 4.6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0MY Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0MY Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-11-30 -7 -23
2019-08-31 -9 -18
2019-05-31 -7 -17
2019-02-28 1 -10 -14
2018-11-30 1 -11 -12
2018-08-31 2 -8 -7
2018-05-31 2 -7 -5
2018-02-28 1 -4 -4
2017-11-30 1 -2 -2
2017-08-31 0 -1 -1
2017-05-31 0 -1 -1
2017-02-28 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if MYM Nutraceuticals is high growth as no earnings estimate data is available.
  • Unable to determine if MYM Nutraceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0MY Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from MYM Nutraceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0MY Past Financials Data
Date (Data in CAD Millions) EPS *
2019-11-30 -0.17
2019-08-31 -0.14
2019-05-31 -0.14
2019-02-28 -0.12
2018-11-30 -0.11
2018-08-31 -0.07
2018-05-31 -0.06
2018-02-28 -0.04
2017-11-30 -0.03
2017-08-31 -0.02
2017-05-31 -0.01
2017-02-28 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MYM Nutraceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine MYM Nutraceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. MYM Nutraceuticals's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. MYM Nutraceuticals's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess MYM Nutraceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MYM Nutraceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

0MY Past Performance

  How has MYM Nutraceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MYM Nutraceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MYM Nutraceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare MYM Nutraceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare MYM Nutraceuticals's 1-year growth to the Europe Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
MYM Nutraceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MYM Nutraceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0MY Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-11-30 -23.22 14.20 0.00
2019-08-31 -18.04 14.13 0.00
2019-05-31 -16.51 12.70 0.06
2019-02-28 0.63 -13.70 11.62 0.06
2018-11-30 1.10 -11.65 9.92 0.06
2018-08-31 1.50 -7.45 8.48 0.06
2018-05-31 1.78 -5.37 6.69
2018-02-28 1.30 -3.79 4.74
2017-11-30 0.82 -2.21 2.65
2017-08-31 0.42 -1.34 1.44
2017-05-31 0.14 -0.85 0.69
2017-02-28 -0.91 0.23
2016-11-30 -0.99 0.20
2016-08-31 -1.06 0.25
2016-05-31 -1.05 0.24
2016-02-29 -0.74 0.22
2015-11-30 -0.61 0.19
2015-08-31 -0.60 0.16
2015-05-31 -0.71 0.27
2015-02-28 -0.46 0.38
2014-11-30 -0.45 0.39
2014-08-31 -0.39 0.38
2014-05-31 -0.27 0.27

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if MYM Nutraceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if MYM Nutraceuticals has efficiently used its assets last year compared to the Europe Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if MYM Nutraceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess MYM Nutraceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MYM Nutraceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

0MY Health

 How is MYM Nutraceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MYM Nutraceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MYM Nutraceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • MYM Nutraceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of MYM Nutraceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 6.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MYM Nutraceuticals Company Filings, last reported 4 months ago.

DB:0MY Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-11-30 6.62 0.35 1.65
2019-08-31 16.25 2.45 2.35
2019-05-31 16.20 0.00 2.40
2019-02-28 19.17 0.00 2.98
2018-11-30 19.11 0.00 2.32
2018-08-31 19.56 0.00 3.98
2018-05-31 19.91 0.00 7.76
2018-02-28 19.17 0.00 10.76
2017-11-30 6.06 0.00 2.41
2017-08-31 1.88 0.00 0.54
2017-05-31 1.51 0.00 0.76
2017-02-28 0.14 0.12 0.41
2016-11-30 -0.29 0.17 0.11
2016-08-31 -0.25 0.17 0.12
2016-05-31 -0.20 0.17 0.15
2016-02-29 0.45 0.65 0.03
2015-11-30 0.54 0.65 0.02
2015-08-31 0.46 0.65 0.03
2015-05-31 0.50 0.65 0.02
2015-02-28 0.90 0.65 0.07
2014-11-30 0.96 0.65 0.10
2014-08-31 1.01 0.12 0.47
2014-05-31 1.01 0.12 0.47
  • MYM Nutraceuticals's level of debt (5.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (67.1% vs 5.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • MYM Nutraceuticals has less than a year of cash runway based on current free cash flow.
  • MYM Nutraceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 61.5% each year.
X
Financial health checks
We assess MYM Nutraceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MYM Nutraceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

0MY Dividends

 What is MYM Nutraceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MYM Nutraceuticals dividends.
If you bought €2,000 of MYM Nutraceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MYM Nutraceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MYM Nutraceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0MY Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 40 Stocks 3.2%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.7%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MYM Nutraceuticals has not reported any payouts.
  • Unable to verify if MYM Nutraceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MYM Nutraceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MYM Nutraceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess MYM Nutraceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MYM Nutraceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MYM Nutraceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

0MY Management

 What is the CEO of MYM Nutraceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Robin Linden
COMPENSATION CA$855,125
TENURE AS CEO 0 years
CEO Bio

Mr. Robin Linden serves as President and Chief Executive Officer at MYM Nutraceuticals Inc. since April 3, 2020. Mr. Linden has been Chief Marketing Officer at MYM Nutraceuticals Inc. since February 25, 2019 and served as its Executive Vice President since February 25, 2019. Mr. Linden served as Interim Corporate Secretary at MYM Nutraceuticals Inc. from December 31, 2019 to April 3, 2020. Mr. Linden served as Interim Chief Financial Officer at MYM Nutraceuticals Inc. since September 30, 2019 until April 3, 2020. Mr. Linden has been with MYM Nutraceuticals Inc. since 2016. Mr. Linden serves as Director at Orion Nutraceuticals Inc. since January 11, 2018. Mr. Linden serves as Director of Special Events and Corporate Partnerships at Fairmont Hotels and Resorts. Mr. Linden has been a Director at MYM Nutraceuticals Inc. since November 29, 2017. He has over many years’ leadership and management experience. He served in leadership and management roles with the University of Manitoba, Molson Breweries Canada and Canadian luxury retailer, Holt Renfrew. Mr. Linden holds a BA (hons) from the University of Manitoba and Post Graduate Diplomas from Simon Fraser University in Vancouver and the University of St. Andrews in Scotland.

CEO Compensation
  • Insufficient data for Robin to compare compensation growth.
  • Robin's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the MYM Nutraceuticals management team in years:

0.7
Average Tenure
  • The average tenure for the MYM Nutraceuticals management team is less than 2 years, this suggests a new team.
Management Team

Robin Linden

TITLE
President
COMPENSATION
CA$855K

Ted Tabisz

TITLE
Interim CFO & Director
COMPENSATION
CA$97K

Mark Forster

TITLE
Chief Financial Officer of International Brands
COMPENSATION
CA$222K
TENURE
0.4 yrs

Erick Factor

TITLE
Chairman & CEO of MYM International Brands
COMPENSATION
CA$318K
TENURE
0.7 yrs

Ronan O'Neill

TITLE
Vice President of Operations
TENURE
0.7 yrs

Billy Casselman

TITLE
Vice President of Commercial Sales & Investor Relations
TENURE
1.2 yrs

Charith Raj Purushothama

TITLE
TENURE
0.3 yrs

Jonathon Iu

TITLE
Head of Research & Development of MJT Production Facility
TENURE
2 yrs

Elizabeth Liu

TITLE
TENURE
0.3 yrs

Andy Kent

TITLE
Executive Independent Director
Board of Directors Tenure

Average tenure of the MYM Nutraceuticals board of directors in years:

1.3
Average Tenure
  • The average tenure for the MYM Nutraceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Howard Steinberg

TITLE
Chairman of the Board
AGE
52
TENURE
0.7 yrs

Robin Linden

TITLE
President
COMPENSATION
CA$855K
TENURE
2.4 yrs

Ted Tabisz

TITLE
Interim CFO & Director
COMPENSATION
CA$97K
TENURE
1.9 yrs

Erick Factor

TITLE
Chairman & CEO of MYM International Brands
COMPENSATION
CA$318K
TENURE
0.7 yrs

Andy Kent

TITLE
Executive Independent Director
TENURE
0.8 yrs

Frank Klees

TITLE
Member of Advisory Board
AGE
68
TENURE
1.7 yrs

Julie Toskan

TITLE
Independent Director of MYM International Brands
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
03. Sep 19 Buy Howard Steinberg Individual 30. Aug 19 30. Aug 19 308,642 €0.22 €68,365
25. Jan 20 Buy Teletouch Services Inc. Company 14. Jan 20 14. Jan 20 1,666,683 €0.04 €68,802
X
Management checks
We assess MYM Nutraceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MYM Nutraceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

0MY News

Simply Wall St News

Who Are The Largest Shareholders In MYM Nutraceuticals Inc (FRA:0MY)?

In this analysis, my focus will be on developing a perspective on MYM Nutraceuticals Inc’s (FRA:0MY) latest ownership structure, a less discussed, but important factor. … Ownership structure has been found to have an impact on shareholder returns in both short- and long-term. … Therefore, it is beneficial for us to examine 0MY's ownership structure in more detail.

Simply Wall St -

Should You Be Concerned About MYM Nutraceuticals Inc's (FRA:0MY) Investors?

In this article, I'm going to take a look at MYM Nutraceuticals Inc’s (DB:0MY) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … See our latest analysis for MYM Nutraceuticals DB:0MY Ownership_summary Apr 30th 18 Insider Ownership Insiders form another group of important ownership types as they manage the company's operations and decide the best use of capital. … With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors.

Simply Wall St -

Before You Buy MYM Nutraceuticals Inc's (FRA:0MY), Consider This

A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one. … MYM Nutraceuticals has a beta of 7.76, which means that the percentage change in its stock value will be higher than the entire market in times of booms and busts. … A high level of beta means investors face higher risk associated with potential gains and losses driven by market movements.

Simply Wall St -

Is This A Catalyst To Buy MYM Nutraceuticals Inc (FRA:0MY)?

Cash is crucial to run a business, and if a company burns through its reserves fast, it will need to come back to market for additional capital raising. … MYM Nutraceuticals may need to come to market again, but the question is, when? … DB:0MY Income Statement Apr 4th 18 When will MYM Nutraceuticals need to raise more cash?

Simply Wall St -

Interested In MYM Nutraceuticals Inc (FRA:0MY)? Here's How It Performed Recently

Today I will examine MYM Nutraceuticals Inc's (DB:0MY) latest earnings update (30 November 2017) and compare these figures against its performance over the past couple of years, in addition to how the rest of 0MY's industry performed. … To account for any quarterly or half-yearly updates, I use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … Inspecting growth from a sector-level, the DE personal products industry has been growing its average earnings by double-digit 16.89% over the past twelve months, and a more subdued 7.94% over the past five years.

Simply Wall St -

0MY Company Info

Description

MYM Nutraceuticals Inc. engages in the cultivation, extraction, and distribution of cannabis products. The company was formerly known as My Marijuana Canada Inc. and changed its name to MYM Nutraceuticals Inc. in February 2016. MYM Nutraceuticals Inc. was incorporated in 2014 and is headquartered in Vancouver, Canada.

Details
Name: MYM Nutraceuticals Inc.
0MY
Exchange: DB
Founded: 2014
CA$8,305,269
168,746,560
Website: http://www.mym.ca
Address: MYM Nutraceuticals Inc.
1095 West Pender Street,
Suite 250,
Vancouver,
British Columbia, V6E 2M6,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX MYM Common Shares Canadian National Stock Exchange CA CAD 03. Nov 2014
OTCPK MYMM.F Common Shares Pink Sheets LLC US USD 03. Nov 2014
DB 0MY Common Shares Deutsche Boerse AG DE EUR 03. Nov 2014
Number of employees
Current staff
Staff numbers
27
MYM Nutraceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 23:44
End of day share price update: 2020/04/07 00:00
Last earnings filing: 2020/01/10
Last earnings reported: 2019/11/30
Last annual earnings reported: 2019/05/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.